{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:18:34Z","timestamp":1794111514966,"version":"4.8.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100003607","name":"Association for Frontotemporal Degeneration","doi-asserted-by":"publisher","award":["2022-0002"],"award-info":[{"award-number":["2022-0002"]}],"id":[{"id":"10.13039\/100003607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metabolic disorders such as insulin resistance and hypertension are potential risk factors for aging and neurodegenerative diseases. These conditions are reversed in Chromogranin A (CgA) knockout (CgA-KO) mice. CgA is known to be associated with protein aggregates in the brains of neurodegenerative diseases including Alzheimer\u2019s disease (AD). Here, we investigated the role of CgA in Tau pathogenesis in AD and corticobasal degeneration (CBD). CgA ablation in Tauopathy mice (PS19) (CgA-KO\/PS19) reduced pathological Tau aggregation and spreading, extended lifespan, and improved cognitive function. Transcriptomic and metabolite analysis of mouse cortices revealed elevated alpha-1-adrenergic receptors (Adra1) expression and high Epinephrine (EPI) levels in PS19 mice compared to WT mice, mirroring observations in AD and CBD patients. CgA depletion in PS19 mice lowered cortical EPI levels and the expression of\n                    <jats:italic>Adra1<\/jats:italic>\n                    back to normal. Treatment of WT hippocampal organotypic slice cultures with EPI or\n                    <jats:italic>Adra1<\/jats:italic>\n                    agonist promoted, while an\n                    <jats:italic>Adra1<\/jats:italic>\n                    antagonist inhibited Tau hyperphosphorylation and formation of neurofibrillary tangles, which is unaltered upon CgA depletion. These findings demonstrate the involvement of CgA in Tau pathogenesis and highlight the interplay between the EPI-Adra1 signaling pathway and CgA in Tauopathy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-59682-6","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T14:38:50Z","timestamp":1747751930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chromogranin A deficiency attenuates tauopathy by altering epinephrine\u2013alpha-adrenergic receptor signaling in PS19 mice"],"prefix":"10.1038","volume":"16","author":[{"given":"Suborno","family":"Jati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Munoz-Mayorga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shandy","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kechun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuren","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-7917","authenticated-orcid":false,"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Litvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6311-7351","authenticated-orcid":false,"given":"Gourisankar","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-0787","authenticated-orcid":false,"given":"Sushil K.","family":"Mahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-3090","authenticated-orcid":false,"given":"Xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"59682_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/215058a0","volume":"215","author":"H Blaschko","year":"1967","unstructured":"Blaschko, H., Comline, R. S., Schneider, F. H., Silver, M. & Smith, A. D. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 215, 58\u201359 (1967).","journal-title":"Nature"},{"key":"59682_CR2","doi-asserted-by":"publisher","first-page":"10999","DOI":"10.1021\/bi700704r","volume":"46","author":"CA Mosley","year":"2007","unstructured":"Mosley, C. A. et al. Biogenesis of the secretory granule: chromogranin A coiled-coil structure results in unusual physical properties and suggests a mechanism for granule core condensation. Biochemistry 46, 10999\u201311012 (2007).","journal-title":"Biochemistry"},{"key":"59682_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0306-4522(92)90222-N","volume":"49","author":"H Winkler","year":"1992","unstructured":"Winkler, H. & Fischer-Colbrie, R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49, 497\u2013528 (1992).","journal-title":"Neuroscience"},{"key":"59682_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1210\/er.2010-0027","volume":"32","author":"A Bartolomucci","year":"2011","unstructured":"Bartolomucci, A. et al. The extended granin family: structure, function, and biomedical implications. Endocr. Rev. 32, 755\u2013797 (2011).","journal-title":"Endocr. Rev."},{"key":"59682_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/01.HYP.13.5.469","volume":"13","author":"M Schober","year":"1989","unstructured":"Schober, M., Howe, P. R., Sperk, G., Fischer-Colbrie, R. & Winkler, H. An increased pool of secretory hormones and peptides in adrenal medulla of stroke-prone spontaneously hypertensive rats. Hypertension 13, 469\u2013474 (1989).","journal-title":"Hypertension"},{"key":"59682_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/080370599439508","volume":"8","author":"DT O\u2019Connor","year":"1999","unstructured":"O\u2019Connor, D. T. et al. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 8, 285\u2013295 (1999).","journal-title":"Blood Press"},{"key":"59682_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1161\/01.HYP.21.5.674","volume":"21","author":"MA Takiyyuddin","year":"1993","unstructured":"Takiyyuddin, M. A. et al. Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension. Hypertension 21, 674\u2013679 (1993).","journal-title":"Hypertension"},{"key":"59682_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0092-8674(01)00459-7","volume":"106","author":"T Kim","year":"2001","unstructured":"Kim, T., Tao-Cheng, J., Eiden, L. E. & Loh, Y. P. Chromogranin A, an \u201cOn\/Off\u201d switch controlling dense-core secretory granule biogenesis. Cell 106, 499\u2013509 (2001).","journal-title":"Cell"},{"key":"59682_CR9","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1242\/jcs.00140","volume":"115","author":"L Taupenot","year":"2002","unstructured":"Taupenot, L. et al. Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A. J. Cell Sci. 115, 4827\u20134841 (2002).","journal-title":"J. Cell Sci."},{"key":"59682_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/324476a0","volume":"324","author":"K Tatemoto","year":"1986","unstructured":"Tatemoto, K. et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324, 476\u2013478 (1986).","journal-title":"Nature"},{"key":"59682_CR11","doi-asserted-by":"publisher","first-page":"28498","DOI":"10.1074\/jbc.M109.020636","volume":"284","author":"JR Gayen","year":"2009","unstructured":"Gayen, J. R. et al. A novel pathway of insulin sensitivity in chromogranin a null mice: A crucial role for pancreastatin in glucose homeostasis. J. Biol. Chem. 284, 28498\u201328509 (2009).","journal-title":"J. Biol. Chem."},{"key":"59682_CR12","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1210\/jc.2005-0408","volume":"90","author":"DT O\u2019Connor","year":"2005","unstructured":"O\u2019Connor, D. T. et al. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J. Clin. Endocrinol. Metab. 90, 5414\u20135425 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"59682_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2337\/db13-1747","volume":"64","author":"GK Bandyopadhyay","year":"2015","unstructured":"Bandyopadhyay, G. K. et al. Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance. Diabetes 64, 104\u2013116 (2015).","journal-title":"Diabetes"},{"key":"59682_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.regpep.2010.02.005","volume":"161","author":"V Sanchez-Margalet","year":"2010","unstructured":"Sanchez-Margalet, V., Gonzalez-Yanes, C., Najib, S. & Santos-Alvarez, J. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul. Pept. 161, 8\u201314 (2010).","journal-title":"Regul. Pept."},{"key":"59682_CR15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1172\/JCI119686","volume":"100","author":"SK Mahata","year":"1997","unstructured":"Mahata, S. K. et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J. Clin. Invest 100, 1623\u20131633 (1997).","journal-title":"J. Clin. Invest"},{"key":"59682_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2337\/db17-0788","volume":"67","author":"W Ying","year":"2018","unstructured":"Ying, W. et al. Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity. Diabetes 67, 841\u2013848 (2018).","journal-title":"Diabetes"},{"key":"59682_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.csbj.2020.02.005","volume":"18","author":"A Dasgupta","year":"2020","unstructured":"Dasgupta, A. et al. Catestatin improves insulin sensitivity by attenuating endoplasmic reticulum stress: In vivo and in silico validation. Comput Struct. Biotechnol. J. 18, 464\u2013481 (2020).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"59682_CR18","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/HYPERTENSIONAHA.120.16809","volume":"77","author":"W Ying","year":"2021","unstructured":"Ying, W. et al. Immunosuppression of macrophages underlies the cardioprotective effects of CST (Catestatin). Hypertension 77, 1670\u20131682 (2021).","journal-title":"Hypertension"},{"key":"59682_CR19","doi-asserted-by":"publisher","first-page":"23141","DOI":"10.1074\/jbc.M111.335877","volume":"287","author":"GK Bandyopadhyay","year":"2012","unstructured":"Bandyopadhyay, G. K. et al. Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J. Biol. Chem. 287, 23141\u201323151 (2012).","journal-title":"J. Biol. Chem."},{"key":"59682_CR20","first-page":"1525","volume":"14","author":"SK Mahata","year":"2000","unstructured":"Mahata, S. K., Mahata, M., Wakade, A. R. & O\u2019Connor, D. T. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): Identification of amino acid residues crucial for activity. Mol. Endocrinol. 14, 1525\u20131535 (2000).","journal-title":"Mol. Endocrinol."},{"key":"59682_CR21","doi-asserted-by":"publisher","first-page":"32058","DOI":"10.1074\/jbc.M305545200","volume":"278","author":"SK Mahata","year":"2003","unstructured":"Mahata, S. K. et al. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter\/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J. Biol. Chem. 278, 32058\u201332067 (2003).","journal-title":"J. Biol. Chem."},{"key":"59682_CR22","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1172\/JCI24354","volume":"115","author":"NR Mahapatra","year":"2005","unstructured":"Mahapatra, N. R. et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J. Clin. Invest 115, 1942\u20131952 (2005).","journal-title":"J. Clin. Invest"},{"key":"59682_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0196-9781(98)00086-2","volume":"19","author":"BP Kennedy","year":"1998","unstructured":"Kennedy, B. P., Mahata, S. K., O\u2019Connor, D. T. & Ziegler, M. G. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19, 1241\u20131248 (1998).","journal-title":"Peptides"},{"key":"59682_CR24","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1161\/HYPERTENSIONAHA.112.202127","volume":"60","author":"N Biswas","year":"2012","unstructured":"Biswas, N. et al. Novel peptide isomer strategy for stable inhibition of catecholamine release: application to hypertension. Hypertension 60, 1552\u20131559 (2012).","journal-title":"Hypertension"},{"key":"59682_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neuroscience.2014.04.001","volume":"270","author":"E Avolio","year":"2014","unstructured":"Avolio, E. et al. Antihypertensive and neuroprotective effects of catestatin in spontaneously hypertensive rats: Interaction with GABAergic transmission in amygdala and brainstem. Neuroscience 270, 48\u201357 (2014).","journal-title":"Neuroscience"},{"key":"59682_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1460-9568.1991.tb00101.x","volume":"3","author":"SK Mahata","year":"1991","unstructured":"Mahata, S. K. et al. Distribution of mRNAs for chromogranins A and B and secretogranin II in rat brain. Eur. J. Neurosci. 3, 895\u2013904 (1991).","journal-title":"Eur. J. Neurosci."},{"key":"59682_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.regpep.2009.11.021","volume":"165","author":"MK Schafer","year":"2010","unstructured":"Schafer, M. K., Mahata, S. K., Stroth, N., Eiden, L. E. & Weihe, E. Cellular distribution of chromogranin A in excitatory, inhibitory, aminergic and peptidergic neurons of the rodent central nervous system. Regul. Pept. 165, 36\u201344 (2010).","journal-title":"Regul. Pept."},{"key":"59682_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0014-5793(90)81408-G","volume":"263","author":"R Weiler","year":"1990","unstructured":"Weiler, R., Lassmann, H., Fischer, P., Jellinger, K. & Winkler, H. A high ratio of chromogranin A to synaptin\/synaptophysin is a common feature of brains in Alzheimer and Pick disease. FEBS Lett. 263, 337\u2013339 (1990).","journal-title":"FEBS Lett."},{"key":"59682_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0006-8993(91)90697-T","volume":"539","author":"JP Brion","year":"1991","unstructured":"Brion, J. P., Couck, A. M., Bruce, M., Anderton, B. & Flament-Durand, J. Synaptophysin and chromogranin A immunoreactivities in senile plaques of Alzheimer\u2019s disease. Brain Res 539, 143\u2013150 (1991).","journal-title":"Brain Res"},{"key":"59682_CR30","first-page":"826","volume":"64","author":"DG Munoz","year":"1991","unstructured":"Munoz, D. G. Chromogranin A-like immunoreactive neurites are major constituents of senile plaques. Lab Invest 64, 826\u2013832 (1991).","journal-title":"Lab Invest"},{"key":"59682_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.exger.2003.09.018","volume":"39","author":"T Lechner","year":"2004","unstructured":"Lechner, T. et al. Chromogranin peptides in alzheimer\u2019s disease. Exp. Gerontol. 39, 101\u2013113 (2004).","journal-title":"Exp. Gerontol."},{"key":"59682_CR32","doi-asserted-by":"publisher","first-page":"13113","DOI":"10.1074\/jbc.M009711200","volume":"276","author":"J Ciesielski-Treska","year":"2001","unstructured":"Ciesielski-Treska, J. et al. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J. Biol. Chem. 276, 13113\u201313120 (2001).","journal-title":"J. Biol. Chem."},{"key":"59682_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12961","volume":"50","author":"O Bousiges","year":"2024","unstructured":"Bousiges, O. et al. Diagnostic value of CSF chromogranin A to discriminate between alzheimer\u2019s disease and dementia with lewy bodies. Neuropathol. Appl Neurobiol. 50, e12961 (2024).","journal-title":"Neuropathol. Appl Neurobiol."},{"key":"59682_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fnins.2015.00220","volume":"9","author":"M Gannon","year":"2015","unstructured":"Gannon, M. et al. Noradrenergic dysfunction in alzheimer\u2019s disease. Front Neurosci. 9, 220 (2015).","journal-title":"Front Neurosci."},{"key":"59682_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fnsyn.2019.00027","volume":"11","author":"K Dyer-Reaves","year":"2019","unstructured":"Dyer-Reaves, K., Goodman, A. M., Nelson, A. R. & McMahon, L. L. Alpha1-adrenergic receptor mediated long-term depression at CA3-CA1 synapses can be induced via accumulation of endogenous norepinephrine and is preserved following noradrenergic denervation. Front Synaptic Neurosci. 11, 27 (2019).","journal-title":"Front Synaptic Neurosci."},{"key":"59682_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.581098","volume":"11","author":"DM Perez","year":"2020","unstructured":"Perez, D. M. alpha(1)-Adrenergic receptors in neurotransmission, synaptic plasticity, and cognition. Front Pharm. 11, 581098 (2020).","journal-title":"Front Pharm."},{"key":"59682_CR37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/CIRCGENETICS.109.924050","volume":"3","author":"JR Gayen","year":"2010","unstructured":"Gayen, J. R. et al. Role of reactive oxygen species in hyperadrenergic hypertension: Biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin A gene. Circ. Cardiovasc Genet 3, 414\u2013425 (2010).","journal-title":"Circ. Cardiovasc Genet"},{"key":"59682_CR38","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1210\/en.2008-0318","volume":"149","author":"T Angelone","year":"2008","unstructured":"Angelone, T. et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine\/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149, 4780\u20134793 (2008).","journal-title":"Endocrinology"},{"key":"59682_CR39","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","volume":"26","author":"S Dujardin","year":"2020","unstructured":"Dujardin, S. et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease. Nat. Med 26, 1256\u20131263 (2020).","journal-title":"Nat. Med"},{"key":"59682_CR40","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson, D. W., Kouri, N., Murray, M. E. & Josephs, K. A. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci. 45, 384\u2013389 (2011).","journal-title":"J. Mol. Neurosci."},{"key":"59682_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure, M. A. & Dickson, D. W. The neuropathological diagnosis of alzheimer\u2019s disease. Mol. Neurodegener. 14, 32 (2019).","journal-title":"Mol. Neurodegener."},{"key":"59682_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.123.21356","volume":"81","author":"A Pacholko","year":"2024","unstructured":"Pacholko, A. & Iadecola, C. Hypertension, neurodegeneration, and cognitive decline. Hypertension 81, 991\u20131007 (2024).","journal-title":"Hypertension"},{"key":"59682_CR43","doi-asserted-by":"crossref","unstructured":"Hobday, A. L. & Parmar, M. S. The link between diabetes mellitus and tau hyperphosphorylation: Implications for risk of alzheimer\u2019s disease. Cureus 13, e18362, (2021).","DOI":"10.7759\/cureus.18362"},{"key":"59682_CR44","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nn.4132","volume":"18","author":"H Asai","year":"2015","unstructured":"Asai, H. et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584\u20131593 (2015).","journal-title":"Nat. Neurosci."},{"key":"59682_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1037465","volume":"13","author":"MA Liu","year":"2022","unstructured":"Liu, M. A. et al. Gut microbial DNA and immune checkpoint gene Vsig4\/CRIg are key antagonistic players in healthy aging and age-associated development of hypertension and diabetes. Front Endocrinol. (Lausanne) 13, 1037465 (2022).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"59682_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337\u2013351 (2007).","journal-title":"Neuron"},{"key":"59682_CR47","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1523\/JNEUROSCI.2642-12.2013","volume":"33","author":"M Iba","year":"2013","unstructured":"Iba, M. et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of alzheimer\u2019s-like tauopathy. J. Neurosci. 33, 1024\u20131037 (2013).","journal-title":"J. Neurosci."},{"key":"59682_CR48","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.febslet.2013.01.051","volume":"587","author":"JL Guo","year":"2013","unstructured":"Guo, J. L. & Lee, V. M. Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett. 587, 717\u2013723 (2013).","journal-title":"FEBS Lett."},{"key":"59682_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-019-0346-0","volume":"14","author":"CL Croft","year":"2019","unstructured":"Croft, C. L., Futch, H. S., Moore, B. D. & Golde, T. E. Organotypic brain slice cultures to model neurodegenerative proteinopathies. Mol. Neurodegener. 14, 45 (2019).","journal-title":"Mol. Neurodegener."},{"key":"59682_CR50","doi-asserted-by":"publisher","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","volume":"111","author":"BB Holmes","year":"2014","unstructured":"Holmes, B. B. et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl Acad. Sci. USA 111, E4376\u2013E4385 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59682_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29552-6","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. Microglial NF-kappaB drives tau spreading and toxicity in a mouse model of tauopathy. Nat. Commun. 13, 1969 (2022).","journal-title":"Nat. Commun."},{"key":"59682_CR52","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1523\/JNEUROSCI.5292-07.2008","volume":"28","author":"MS Montesinos","year":"2008","unstructured":"Montesinos, M. S. et al. The crucial role of chromogranins in storage and exocytosis revealed using chromaffin cells from chromogranin A null mouse. J. Neurosci. 28, 3350\u20133358 (2008).","journal-title":"J. Neurosci."},{"key":"59682_CR53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1474-8673.1994.tb00601.x","volume":"14","author":"MA Takiyyuddin","year":"1994","unstructured":"Takiyyuddin, M. A. et al. Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. J. Auton. Pharm. 14, 187\u2013200 (1994).","journal-title":"J. Auton. Pharm."},{"key":"59682_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jnc.15603","volume":"161","author":"ZY Yu","year":"2022","unstructured":"Yu, Z. Y. et al. Inhibiting alpha1-adrenergic receptor signaling pathway ameliorates AD-type pathologies and behavioral deficits in APPswe\/PS1 mouse model. J. Neurochem 161, 293\u2013307 (2022).","journal-title":"J. Neurochem"},{"key":"59682_CR55","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/00498250802001826","volume":"38","author":"JC Erve","year":"2008","unstructured":"Erve, J. C. et al. Metabolism of prazosin in rat and characterization of metabolites in plasma, urine, faeces, brain and bile using liquid chromatography\/mass spectrometry (LC\/MS). Xenobiotica 38, 540\u2013558 (2008).","journal-title":"Xenobiotica"},{"key":"59682_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01901-5","volume":"12","author":"K Henjum","year":"2022","unstructured":"Henjum, K. et al. Cerebrospinal fluid catecholamines in alzheimer\u2019s disease patients with and without biological disease. Transl. Psychiatry 12, 151 (2022).","journal-title":"Transl. Psychiatry"},{"key":"59682_CR57","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0893-133X(98)00054-2","volume":"19","author":"ER Peskind","year":"1998","unstructured":"Peskind, E. R. et al. Cerebrospinal fluid epinephrine in alzheimer\u2019s disease and normal aging. Neuropsychopharmacology 19, 465\u2013471 (1998).","journal-title":"Neuropsychopharmacology"},{"key":"59682_CR58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/112_2020_55","volume":"179","author":"J Sanchez-Collado","year":"2021","unstructured":"Sanchez-Collado, J., Lopez, J. J., Jardin, I., Salido, G. M. & Rosado, J. A. Cross-talk between the adenylyl cyclase\/cAMP pathway and Ca(2+) homeostasis. Rev. Physiol. Biochem Pharm. 179, 73\u2013116 (2021).","journal-title":"Rev. Physiol. Biochem Pharm."},{"key":"59682_CR59","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.pharmthera.2006.11.006","volume":"113","author":"BP Ramos","year":"2007","unstructured":"Ramos, B. P. & Arnsten, A. F. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharm. Ther. 113, 523\u2013536 (2007).","journal-title":"Pharm. Ther."},{"key":"59682_CR60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.tips.2015.02.006","volume":"36","author":"SZ Langer","year":"2015","unstructured":"Langer, S. Z. alpha2-Adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharm. Sci. 36, 196\u2013202 (2015).","journal-title":"Trends Pharm. Sci."},{"key":"59682_CR61","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.106.628859","volume":"115","author":"F Rao","year":"2007","unstructured":"Rao, F. et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115, 2271\u20132281 (2007).","journal-title":"Circulation"},{"key":"59682_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1471-4159.1997.68010047.x","volume":"68","author":"MA Reutter","year":"1997","unstructured":"Reutter, M. A., Richards, E. M. & Sumners, C. Regulation of alpha 2A-adrenergic receptor mRNA in rat astroglial cultures: role of cyclic AMP and protein kinase C. J. Neurochem 68, 47\u201357 (1997).","journal-title":"J. Neurochem"},{"key":"59682_CR63","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.neurobiolaging.2012.09.010","volume":"34","author":"L Katsouri","year":"2013","unstructured":"Katsouri, L. et al. Prazosin, an alpha(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer\u2019s disease. Neurobiol. Aging 34, 1105\u20131115 (2013).","journal-title":"Neurobiol. Aging"},{"key":"59682_CR64","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/alz.12325","volume":"17","author":"D Datta","year":"2021","unstructured":"Datta, D. et al. Age-related calcium dysregulation linked with tau pathology and impaired cognition in non-human primates. Alzheimers Dement 17, 920\u2013932 (2021).","journal-title":"Alzheimers Dement"},{"key":"59682_CR65","doi-asserted-by":"publisher","first-page":"R187","DOI":"10.1152\/ajpregu.00054.2013","volume":"305","author":"PG Guyenet","year":"2013","unstructured":"Guyenet, P. G. et al. C1 neurons: the body\u2019s EMTs. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R187\u2013R204 (2013).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"59682_CR66","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/221368a0","volume":"221","author":"RD Ciaranello","year":"1969","unstructured":"Ciaranello, R. D., Barchas, R. E., Byers, G. S., Stemmle, D. W. & Barchas, J. D. Enzymatic synthesis of adrenaline in mammalian brain. Nature 221, 368\u2013369 (1969).","journal-title":"Nature"},{"key":"59682_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0026-895X(25)13697-3","volume":"9","author":"TH Joh","year":"1973","unstructured":"Joh, T. H. & Goldstein, M. Isolation and characterization of multiple forms of phenylethanolamine N-methyltransferase. Mol. Pharm. 9, 117\u2013129 (1973).","journal-title":"Mol. Pharm."},{"key":"59682_CR68","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0006-8993(94)91177-0","volume":"661","author":"WJ Burke","year":"1994","unstructured":"Burke, W. J. et al. Degenerative changes in epinephrine tonic vasomotor neurons in alzheimer\u2019s disease. Brain Res 661, 35\u201342 (1994).","journal-title":"Brain Res"},{"key":"59682_CR69","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1532-5415.1990.tb03448.x","volume":"38","author":"WJ Burke","year":"1990","unstructured":"Burke, W. J., Chung, H. D., Marshall, G. L., Gillespie, K. N. & Joh, T. H. Evidence for decreased transport of PNMT protein in advanced alzheimer\u2019s disease. J. Am. Geriatr. Soc. 38, 1275\u20131282 (1990).","journal-title":"J. Am. Geriatr. Soc."},{"key":"59682_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0361-9230(98)00062-8","volume":"47","author":"EJ Van Bockstaele","year":"1998","unstructured":"Van Bockstaele, E. J. Morphological substrates underlying opioid, epinephrine and gamma-aminobutyric acid inhibitory actions in the rat locus coeruleus. Brain Res Bull. 47, 1\u201315 (1998).","journal-title":"Brain Res Bull."},{"key":"59682_CR71","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00424-024-02999-w","volume":"476","author":"M Ghasemi","year":"2024","unstructured":"Ghasemi, M. & Mehranfard, N. Neuroprotective actions of norepinephrine in neurological diseases. Pflug. Arch. 476, 1703\u20131725 (2024).","journal-title":"Pflug. Arch."},{"key":"59682_CR72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ibra.12001","volume":"7","author":"HL Zou","year":"2021","unstructured":"Zou, H. L., Li, J., Zhou, J. L., Yi, X. & Cao, S. Effects of norepinephrine on microglial neuroinflammation and neuropathic pain. Ibrain 7, 309\u2013317 (2021).","journal-title":"Ibrain"},{"key":"59682_CR73","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s12035-018-1235-1","volume":"56","author":"S Song","year":"2019","unstructured":"Song, S. et al. Loss of brain norepinephrine elicits neuroinflammation-mediated oxidative injury and selective caudo-rostral neurodegeneration. Mol. Neurobiol. 56, 2653\u20132669 (2019).","journal-title":"Mol. Neurobiol."},{"key":"59682_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104706","volume":"135","author":"E Saboory","year":"2020","unstructured":"Saboory, E., Ghasemi, M. & Mehranfard, N. Norepinephrine, neurodevelopment and behavior. Neurochem Int 135, 104706 (2020).","journal-title":"Neurochem Int"},{"key":"59682_CR75","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke, V. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564, 273\u2013277 (2018).","journal-title":"Nature"},{"key":"59682_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.neures.2018.05.001","volume":"136","author":"C Abe","year":"2018","unstructured":"Abe, C. & Inoue, T. Role of C1 neurons in anti-inflammatory reflex: Mediation between afferents and efferents. Neurosci. Res 136, 6\u201312 (2018).","journal-title":"Neurosci. Res"},{"key":"59682_CR77","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00441-015-2316-3","volume":"363","author":"T Pasqua","year":"2016","unstructured":"Pasqua, T. et al. Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo. Cell Tissue Res 363, 693\u2013712 (2016).","journal-title":"Cell Tissue Res"},{"key":"59682_CR78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1161\/CIRCULATIONAHA.107.709105","volume":"118","author":"DT O\u2019Connor","year":"2008","unstructured":"O\u2019Connor, D. T. et al. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation 118, 247\u2013257 (2008).","journal-title":"Circulation"},{"key":"59682_CR79","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-0716-2671-9_22","volume":"2565","author":"K Tang","year":"2023","unstructured":"Tang, K. & Mahata, S. K. Determination of catecholamines in a small volume (25 muL) of plasma from conscious mouse tail vein. Methods Mol. Biol. 2565, 331\u2013342 (2023).","journal-title":"Methods Mol. Biol."},{"key":"59682_CR80","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00213-018-5001-x","volume":"236","author":"EK Lucas","year":"2019","unstructured":"Lucas, E. K., Wu, W. C., Roman-Ortiz, C. & Clem, R. L. Prazosin during fear conditioning facilitates subsequent extinction in male C57Bl\/6N mice. Psychopharmacol. (Berl.) 236, 273\u2013279 (2019).","journal-title":"Psychopharmacol. (Berl.)"},{"key":"59682_CR81","unstructured":"Jati, S. https:\/\/BioRender.com\/b31o629 (2025)."},{"key":"59682_CR82","unstructured":"Rossitto, L. https:\/\/BioRender.com\/24ecnxt (2025)."},{"key":"59682_CR83","unstructured":"Jati, S. https:\/\/BioRender.com\/rlcspdq (2025)."},{"key":"59682_CR84","unstructured":"Jati, S. https:\/\/BioRender.com\/l88w543 (2025)."},{"key":"59682_CR85","unstructured":"Jati, S. https:\/\/BioRender.com\/y60r220 (2025)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59682-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59682-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59682-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:02:15Z","timestamp":1778090535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59682-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59682"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59682-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4797912\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K.M. is the founder of CgA Therapeuticals, Inc. GG and SKM are the founders of Siraj Therapeutics. I.L. is a member of the Scientific Advisory Board for the Rossy PSP Program at the University of Toronto, Aprinoia, Amydis, and the Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee. She receives her salary from the University of California, San Diego, and as Chief Editor of\n                      Frontiers in Neurology\n                      . The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4703"}}